S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrion Co. stock logo
ATRI
Atrion
$385.70
-3.3%
$400.65
$274.98
$670.00
$678.83M0.616,906 shs25,747 shs
Cerus Co. stock logo
CERS
Cerus
$1.64
$2.03
$1.21
$3.08
$297.30M1.291.55 million shs764,284 shs
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$24.04
$24.02
$8.42
$24.25
$1.76B3.022.70 million shsN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$1.36
$1.23
$0.75
$7.44
$8.43M-1.119,470 shs435 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrion Co. stock logo
ATRI
Atrion
-2.53%-6.74%-7.74%+20.11%-33.52%
Cerus Co. stock logo
CERS
Cerus
-2.38%-3.81%-11.83%-2.96%-39.71%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%+0.20%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%-4.23%+0.74%+33.01%-67.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atrion Co. stock logo
ATRI
Atrion
1.4851 of 5 stars
0.01.02.50.02.43.31.3
Cerus Co. stock logo
CERS
Cerus
2.8289 of 5 stars
3.33.00.00.03.92.50.6
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.2395 of 5 stars
0.00.00.04.20.01.70.6
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/A
Cerus Co. stock logo
CERS
Cerus
2.67
Moderate Buy$3.50113.41% Upside
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/A

Current Analyst Ratings

Latest GNMK, CERS, CSII, VAPO, and ATRI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
Cerus Co. stock logo
CERS
Cerus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/7/2024
Cerus Co. stock logo
CERS
Cerus
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$2.50
3/6/2024
Cerus Co. stock logo
CERS
Cerus
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$3.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atrion Co. stock logo
ATRI
Atrion
$169.33M4.01$18.49 per share20.86$138.02 per share2.79
Cerus Co. stock logo
CERS
Cerus
$156.37M1.90N/AN/A$0.29 per share5.66
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$88.02M19.96N/AN/A$0.21 per share114.48
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.12N/AN/A($9.01) per share-0.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atrion Co. stock logo
ATRI
Atrion
$19.41M$11.0334.97N/A11.46%8.07%7.37%5/13/2024 (Estimated)
Cerus Co. stock logo
CERS
Cerus
-$37.49M-$0.21N/AN/AN/A-23.98%-67.17%-17.68%5/2/2024 (Estimated)
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
-$47.35M-$0.82N/AN/AN/A-16.95%-39.36%-13.02%N/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$9.90N/AN/A-84.74%N/A-65.84%5/1/2024 (Estimated)

Latest GNMK, CERS, CSII, VAPO, and ATRI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/5/2024Q4 2023
Cerus Co. stock logo
CERS
Cerus
-$0.01-$0.01N/A-$0.01$46.80 million$46.77 million
2/29/2024Q4 2023
Atrion Co. stock logo
ATRI
Atrion
N/A$3.65+$3.65$3.65N/A$43.58 million
2/22/2024Q4 2023
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A-$1.60-$1.60-$1.60N/A$19.73 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atrion Co. stock logo
ATRI
Atrion
$8.802.28%+9.65%79.78%21 Years
Cerus Co. stock logo
CERS
Cerus
N/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A

Latest GNMK, CERS, CSII, VAPO, and ATRI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/27/2024
Atrion Co. stock logo
ATRI
Atrion
Quarterly$2.202.42%3/14/20243/15/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atrion Co. stock logo
ATRI
Atrion
N/A
9.09
2.57
Cerus Co. stock logo
CERS
Cerus
1.12
2.14
1.55
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.75
4.33
3.84
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
2.43
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Atrion Co. stock logo
ATRI
Atrion
66.19%
Cerus Co. stock logo
CERS
Cerus
78.37%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
96.94%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%

Insider Ownership

CompanyInsider Ownership
Atrion Co. stock logo
ATRI
Atrion
22.70%
Cerus Co. stock logo
CERS
Cerus
7.05%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
3.25%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Atrion Co. stock logo
ATRI
Atrion
7121.76 million1.36 millionNot Optionable
Cerus Co. stock logo
CERS
Cerus
625181.28 million168.50 millionOptionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
61873.09 millionN/AOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
1826.20 million5.22 millionOptionable

GNMK, CERS, CSII, VAPO, and ATRI Headlines

SourceHeadline
Onymos Powers Connected Cloud App for Global Medical Technology Company, VapothermOnymos Powers Connected Cloud App for Global Medical Technology Company, Vapotherm
dbta.com - March 25 at 5:37 PM
Vapotherm to debut home ventilator to improve patient careVapotherm to debut home ventilator to improve patient care
msn.com - March 20 at 7:36 PM
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
finance.yahoo.com - March 20 at 7:36 PM
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
finance.yahoo.com - March 15 at 10:23 AM
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherms High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfortDr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
prnewswire.com - March 6 at 6:45 AM
Vapotherms HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South Americas Largest Health Care MarketVapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
prnewswire.com - February 29 at 6:45 AM
Vapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - February 23 at 7:30 AM
Vapotherm: Q4 Earnings SnapshotVapotherm: Q4 Earnings Snapshot
chron.com - February 22 at 9:28 PM
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
prnewswire.com - February 22 at 4:10 PM
Innovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market DynamicsInnovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market Dynamics
opprairie.com - February 12 at 10:06 AM
Vapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And ExhibitsVapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And Exhibits
cbonds.com - December 17 at 8:45 AM
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQXOTC Markets Group Welcomes Vapotherm, Inc. to OTCQX
financialpost.com - December 15 at 7:08 AM
NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)
finance.yahoo.com - December 14 at 8:20 PM
Vapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting PlanVapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting Plan
marketwatch.com - December 14 at 8:20 PM
Vapotherm Shares Decline 22% on Voluntary Delisting Grom NYSEVapotherm Shares Decline 22% on Voluntary Delisting Grom NYSE
marketwatch.com - December 11 at 1:11 PM
Vapotherm slips on announcing voluntary delisting from NYSE to OTCQX MarketplaceVapotherm slips on announcing voluntary delisting from NYSE to OTCQX Marketplace
msn.com - December 11 at 8:11 AM
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXVapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
finance.yahoo.com - December 11 at 8:11 AM
Vapotherm Educates over 8,000 Clinicians in Respiratory Care MonthVapotherm Educates over 8,000 Clinicians in Respiratory Care Month
finance.yahoo.com - November 28 at 8:21 PM
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call TranscriptVapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 2:28 PM
Vapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52MVapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52M
msn.com - November 8 at 7:38 PM
Vapotherm Reports Third Quarter 2023 Financial ResultsVapotherm Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 7:38 PM
Vapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo FinanceVapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - November 8 at 9:36 AM
Earnings Outlook For VapothermEarnings Outlook For Vapotherm
benzinga.com - November 7 at 6:13 PM
Vapotherm To Report Third Quarter 2023 Financial ResultsVapotherm To Report Third Quarter 2023 Financial Results
finance.yahoo.com - November 1 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Atrion logo

Atrion

NASDAQ:ATRI
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Cerus logo

Cerus

NASDAQ:CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Cardiovascular Systems logo

Cardiovascular Systems

NASDAQ:CSII
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.
GenMark Diagnostics logo

GenMark Diagnostics

NASDAQ:GNMK
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.
Vapotherm logo

Vapotherm

NYSE:VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.